Leerink Partnrs Comments on MoonLake Immunotherapeutics’ FY2023 Earnings (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTXFree Report) – Analysts at Leerink Partnrs raised their FY2023 earnings per share (EPS) estimates for shares of MoonLake Immunotherapeutics in a research note issued to investors on Monday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings of ($0.81) per share for the year, up from their prior forecast of ($0.82). The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($0.85) per share. Leerink Partnrs also issued estimates for MoonLake Immunotherapeutics’ Q4 2023 earnings at ($0.19) EPS, Q1 2024 earnings at ($0.20) EPS, Q2 2024 earnings at ($0.22) EPS, Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.27) EPS, FY2024 earnings at ($0.92) EPS, FY2025 earnings at ($1.25) EPS, FY2026 earnings at ($1.90) EPS and FY2027 earnings at ($2.32) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTXGet Free Report) last released its quarterly earnings data on Tuesday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05.

Other analysts also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of MoonLake Immunotherapeutics in a research note on Monday, November 27th. Stifel Nicolaus lifted their target price on MoonLake Immunotherapeutics from $66.00 to $69.00 and gave the company a “buy” rating in a research note on Monday, December 18th. Wedbush reaffirmed an “outperform” rating and set a $92.00 target price on shares of MoonLake Immunotherapeutics in a research note on Friday, December 1st. Guggenheim lifted their target price on MoonLake Immunotherapeutics from $70.00 to $77.00 and gave the company a “buy” rating in a research note on Wednesday, November 15th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $78.00 target price on shares of MoonLake Immunotherapeutics in a research note on Wednesday, November 8th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, MoonLake Immunotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $72.20.

View Our Latest Report on MLTX

MoonLake Immunotherapeutics Price Performance

Shares of MoonLake Immunotherapeutics stock opened at $61.25 on Thursday. The business’s fifty day moving average price is $57.14 and its two-hundred day moving average price is $54.19. The company has a market capitalization of $3.83 billion, a P/E ratio of -64.47 and a beta of 1.30. MoonLake Immunotherapeutics has a 1-year low of $13.63 and a 1-year high of $63.78.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. UBS Group AG purchased a new position in shares of MoonLake Immunotherapeutics during the second quarter valued at $387,000. FMR LLC purchased a new position in shares of MoonLake Immunotherapeutics during the second quarter valued at $6,264,000. Millennium Management LLC purchased a new position in shares of MoonLake Immunotherapeutics during the second quarter valued at $147,000. Citadel Advisors LLC purchased a new position in shares of MoonLake Immunotherapeutics during the second quarter valued at $13,916,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in shares of MoonLake Immunotherapeutics during the second quarter valued at $4,439,000.

Insider Transactions at MoonLake Immunotherapeutics

In other news, CFO Matthias Bodenstedt sold 94,736 shares of the business’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $59.22, for a total transaction of $5,610,265.92. Following the sale, the chief financial officer now directly owns 526,167 shares of the company’s stock, valued at $31,159,609.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 15.27% of the stock is owned by insiders.

MoonLake Immunotherapeutics Company Profile

(Get Free Report)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis.

Further Reading

Earnings History and Estimates for MoonLake Immunotherapeutics (NASDAQ:MLTX)

Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.